NASDAQ:LEGN 8 December 2025

Legend Biotech jumps 42% as traders look at results from small cancer study

Legend Biotech Corporation shares are coming off a 42% rally on Tuesday, trading on the Nasdaq. Investors are still digesting early cancer-drug trial results that lifted hopes for the pipeline behind the company’s approved multiple myeloma drug Carvykti.

3 June 2026

Biotechnology·Healthcare News·NASDAQ:LEGN·Stock Market

Legend Biotech Stock Jumps on Full Response in Small Trial as Traders React Quickly

Legend Biotech shares jumped over 35% midday Tuesday in New York after the company released early data on a new blood-cancer drug that attempts to generate cancer-fighting immune cells inside patients. The stock was last at $34.48, close to its session peak of $35.33, with trading volume well above normal.

2 June 2026

NASDAQ:LEGN·Stock Market

Legend Biotech (LEGN) stock slips in premarket after 9% surge as Gilead-Arcellx deal spotlights Carvykti rivals

Legend Biotech slipped 0.2% to $19.72 early Tuesday, following a 9% surge the previous session that left shares at $19.75. On Monday, the stock ranged from $18.94 up to $21.58, with roughly 6.2 million shares changing hands.

24 February 2026

NASDAQ:LEGN·Stock Market

Arcellx stock surges toward $115 buyout price after Gilead deal sets new ceiling

Shares of Arcellx surged roughly 78% to $113.92 Monday morning, following news that Gilead Sciences will acquire the cancer therapy maker—pushing the stock close to the buyout price. The takeover puts Arcellx’s valuation as high as $7.8 billion, factoring in a contingent sales-related bonus.

23 February 2026

NASDAQ:ACLX·NASDAQ:GILD·NASDAQ:LEGN·NYSE:JNJ·Stock Market

Legend Biotech (LEGN) stock jumps after Oppenheimer starts coverage with $75 target

Shares of Legend Biotech Corp rose 7.4% to $22.53 in midday trading on Wednesday after Oppenheimer initiated coverage with an “Outperform” rating and set a $75 price target, according to MarketBeat. StreetInsider said Oppenheimer analyst Trevor Allred authored the initiation note. MarketBeat

7 January 2026

NASDAQ:LEGN·Stock Market

Legend Biotech stock hits a fresh 52-week low as biotech lags — JPMorgan update looms

Legend Biotech Corp shares fell 4.7% to $20.49 on Monday, after touching $20.29 — a fresh 52-week low — in afternoon trading. The stock is about 55% below its 52-week high of $45.30. SoFi

5 January 2026

NASDAQ:LEGN·Stock Market

Biggest Stock Losers Today in the U.S. (Dec. 10, 2025): DYN, SLM, KTB, WAY and More Slide as Fed Decision Looms

U.S. stocks are trading in a holding pattern on Wednesday, December 10, 2025, as Wall Street waits for the Federal Reserve’s final interest‑rate decision of the year. Index moves are modest, but beneath the surface a cluster of mid‑cap names is posting double‑digit percentage declines, led by Dyne Therapeutics, SLM Corp, Kontoor Brands and Waystar Holding. Investing.com+1

10 December 2025

Federal Reserve·NASDAQ:DYN·NASDAQ:LEGN·NASDAQ:MBX·NASDAQ:NRIX·NASDAQ:SLM·NASDAQ:SMMT·NASDAQ:WAY·NYSE:AAP·NYSE:GPK·NYSE:KTB·Stock Market

Legend Biotech (LEGN) Stock Hits New Lows: Oversold CAR-T Leader or Long-Term Opportunity?

As of December 9, 2025, shares of Legend Biotech Corporation are under heavy pressure even as the company posts strong growth from its flagship CAR-T therapy, CARVYKTI. Here’s a deep dive into the latest news, forecasts, analyst calls and technical signals that are driving sentiment around Legend Biotech stock today.

9 December 2025

NASDAQ:LEGN·Stock Market

Legend Biotech (LEGN) Stock Hits 52‑Week Low After UBS Cut: December 8, 2025 News, Outlook and Forecast

Legend Biotech Corp. shares are under heavy pressure on December 8, 2025, trading in the mid‑$20s and touching a new 52‑week low around $25.66 during the session. The slide comes despite strong clinical momentum for its flagship CAR‑T therapy CARVYKTI® and robust revenue growth, as investors react to valuation resets and ongoing concerns about profitability and cash flow. Investing.com+1

8 December 2025

Financial Forecasts·NASDAQ:LEGN·Stock Market

Biggest Stock Losers Today: LEGN, MRVL, UL and More Slide as Wall Street Braces for a Fed Rate Cut (December 8, 2025)

Wall Street kicked off “Fed week” in a cautious mood on Monday, December 8, 2025. U.S. stock futures ticked slightly higher, with the S&P 500 hovering just below record territory as traders priced in an ~85–90% chance of another 25‑basis‑point rate cut at the Federal Reserve’s final meeting of the year. TechStock²+1

8 December 2025

Federal Reserve·NASDAQ:INCY·NASDAQ:LCID·NASDAQ:LEGN·NASDAQ:MRVL·NASDAQ:PRCT·NASDAQ:VKTX·NYSE:APD·NYSE:DG·NYSE:HL·NYSE:PSN·NYSE:UL·Stock Market

NASDAQ:LEGN 8 December 2025 - 3 June 2026